Enzymatic radiosynthesis of deoxy-[18f]fluorocellobiose and deoxy-[18f]fluorocellotriose

HK40137447APending Publication Date: 2026-09-11THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125879
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-27
Filing Date
2026-07-08
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Enzymatic radiosyntheses of deoxy-[18F]fluorocellobiose and deoxy-[18F]fluorocellotriose are disclosed. Deoxy-[18F]fluorocellobiose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, and a cellobiose phosphorylase (CBP), or (ii) deoxy-[18F]fluoroglucose-1-phosphate, glucose, and a CBP. Deoxy-[18F]fluorocellotriose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, CBP, and a CBP variant, (ii) deoxy-[18F]fluorocellobiose, glucose-1-phosphate, and a CBP variant, or (iii) deoxy-[18F]fluoroglucose-1-phosphate, cellobiose, and a CBP variant.
Need to check novelty before this filing date? Find Prior Art

Description

Enzymatic radiosynthesis methods for deoxy-[18F]fluorocellobiose and deoxy-[18F]fluorocellotriose are disclosed. The deoxy-[18F]fluorocellobiose is synthesized within 1-2 hours by: (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, and cellobiose phosphorylase (CBP); or (ii) deoxy-[18F]fluoroglucose-1-phosphate, glucose, and CBP. The deoxy-[18F]fluorocellotriose is synthesized within 1-2 hours by: (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, CBP, and CBP variants; (ii) deoxy-[18F]fluorocellobiose, glucose-1-phosphate, and CBP variants; or (iii) deoxy-[18F]fluoroglucose-1-phosphate, cellobiose, and CBP variants. Abstract

Claims

4239-109758-02 E-080-2023-0-PCT-02We claim:

1. A method for enzymatic radiosynthesis of deoxy-[18F]fluorocellobiose, deoxy- [18F]fluorocellotriose, or both, the method comprising: (A) (i) combining deoxy-[18F]fluoroglucose ([18F]FDG) with glucose-1-phosphate (Glc- 1P), a cellobiose phosphorylase (CBP), and optionally a CBP variant to provide a first solution having at least a 10-fold molar excess of the Glc-1P relative to the [18F]FDG, and (ii) incubating the first solution at a temperature of from 25 °C to 45 °C for a time of from 1 hour to 2 hours to provide a second solution comprising deoxy- [18F]fluorocellobiose if the CBP variant is absent or a subsequent solution comprising deoxy-[18F]fluorocellotriose if the CBP variant is present; or (B) (i) phosphorylating [18F]FDG to form deoxy-[18F]fluoroglucose-1-phosphate ([18F]FGlc-1P), (ii) combining the [18F]FGlc-1P with glucose and a solution comprising a CBP to provide a first solution having at least a 10-fold molar excess of the glucose relative to the [18F]FGlc-1P, and (iii) incubating the first solution at a temperature of from 25 °C to 45 °C for a time of from 1 hour to 2 hours to provide a second solution comprising deoxy- [18F]fluorocellobiose, wherein the [18F]FDG has a structure according to (I), where one or more of R1, R2, R3, and R4is18F and the others of R1, R2,and wherein, in step (A)(i), R3is -OH.

2. The method of claim 1, wherein: (i) an initial amount of the [18F]FDG is from 1 mCi to 200 mCi; or (ii) in step A(i) an initial concentration of the Glc-1P is from 50 mM to 200 mM, or in step (B)(ii) an initial concentration of the glucose is from 50 mM to 200 mM; or (iii) an amount of the CBP is from 0.5 mg to 2 mg; (iv) an amount of the CBP variant, if present in step (A)(i), is from 0.5 mg to 2 mg; or (v) any combination of two or more of (i), (ii), (iii), and (iv).4239-109758-02 E-080-2023-0-PCT-023. The method of claim 1 or claim 2, wherein the [18F]FDG ,combination thereof.

4. The method of claim 3, wherein the [18F]FDG .

5. The method of any one of claims 1-4, wherein the method is an automated method and steps (A)(i) and (A)(ii) comprise: (A) (i) using an automated system to combine the GLC-1P with the CBP, and optionally the CBP variant, in a reactor and to add the ([18F]FDG to the reactor; and (A) (ii) using the automated system to incubate the first solution at the temperature of from 25 °C to 45 °C for the time of from 1 hour to 2 hours.

6. The method of any one of claims 1-5, wherein the second solution comprising deoxy-[18F]fluorocellobiose further comprises (A) CBP and unreacted Glc-1P or (B) CBP and unreacted glucose, the method further comprising separating the CBP from the second solution to provide a deoxy-[18F]fluorocellobiose solution.

7. The method of claim 6, wherein separating the CBP from the second solution comprises: adding a C1-C3alkanol to the second solution to precipitate (A) the CBP and unreacted Glc- 1P or (B) the CBP; and removing (A) the precipitated CBP and the precipitated unreacted Glc-1P or (B) the precipitated CBP to provide the deoxy-[18F]fluorocellobiose solution.

8. The method of claim 6, wherein separating the CBP from the second solution comprises: heating the second solution at a temperature of from 80 °C to 120 °C for 5 minutes to 15 minutes to precipitate the CBP; and removing the CBP to provide the deoxy-[18F]fluorocellobiose solution.4239-109758-02 E-080-2023-0-PCT-029. The method of claim 6, wherein the method is an automated method and separating (A) the CBP and the unreacted Glc-1P from the second solution comprises: using the automated system to incubate the second solution at a temperature of 80 °C to 120 °C for an effective amount of time to precipitate the CBP; and using the automated system to filter the second solution to remove the precipitated CBP from the second solution to provide a deoxy-[18F]fluorocellobiose solution.

10. The method of any one of claims 7-9, further comprising purifying the deoxy- [18F]fluorocellobiose solution by: (i) flowing the deoxy-[18F]fluorocellobiose solution through a solid-phase extraction (SPE) cartridge, whereby the deoxy-[18F]fluorocellobiose solution is retained in the SPE cartridge, and eluting the deoxy-[18F]fluorocellobiose from the SPE cartridge by flowing an eluent through the SPE cartridge; or (ii) using the automated system to flow the deoxy-[18F]fluorocellobiose solution through a solid-phase extraction (SPE) cartridge, whereby the deoxy-[18F]fluorocellobiose solution is retained in the SPE cartridge, and using the automated system to elute the deoxy-[18F]fluorocellobiose from the SPE cartridge by flowing an eluent through the SPE cartridge.

11. The method of any one of claims 1-10, wherein: (i) the CBP variant is absent and following step (A)(ii), the deoxy-[18F]fluorocellobiose has a structure according to Formula II or (ii) following stepa structure according to Formula III .4239-109758-02 E-080-2023-0-PCT-0212. The method of claim 11, wherein: (a) the deoxy-[18F]fluorocellobiose has a structure according to Formula II and the deoxy- [18F]fluorocellobiose is , (b) the and the deoxy- 18[ F]13. The method of claim 12, wherein the deoxy-[18F]fluorocellobiose is:

14. The method of claim 1, wherein: steps (A)(i) and (A)(ii) are performed; the CBP variant is present; and incubating the first solution at the temperature of from 25 °C to 45 °C for the time of from 1 hour to 2 hours provides the subsequent solution comprising deoxy-[18F]fluorocellotriose, wherein the deoxy-[18F]fluorocellotriose has a structure according to Formula IV .4239-109758-02 E-080-2023-0-PCT-0215. The method of claim 14, wherein the deoxy-[18F]fluorocellotriose is: ,or an further comprising: using an automated system to combine the [18F]FDG, Glc-1P, CBP and CBP variant to form the first solution; and using the automated system to incubate the first solution at the temperature of from 25 °C to 45 °C for the time of from 1 hour to 2 hours to provide the subsequent solution comprising deoxy- [18F]fluorocellotriose.

17. The method of any one of claims 14-16, wherein the subsequent solution further comprises CBP and the CBP variant, the method further comprising separating the CBP and the CBP variant from the deoxy-[18F]fluorocellotriose to provide a deoxy-[18F]fluorocellotriose solution.

18. The method of claim 17, wherein separating the CBP and the CBP variant from the subsequent solution comprises: adding a C1-C3alkanol to the subsequent solution to precipitate the CBP, the CBP variant, and unreacted Glc-1P; and removing the precipitated CBP, the precipitated CBP variant, and the precipitated unreacted Glc-1P to provide the deoxy-[18F]fluorocellotriose solution.

19. The method of claim 17, wherein separating the CBP variant from the subsequent solution comprises: heating the subsequent solution at a temperature of from 80 °C to 120 °C for 5 minutes to 15 minutes to precipitate the CBP and the CBP variant; and removing the CBP and the CBP variant to provide the deoxy-[18F]fluorocellotriose solution.4239-109758-02 E-080-2023-0-PCT-0220. The method of claim 17, wherein the method is an automated method and separating the CBP and the CBP variant from the subsequent solution comprises: using the automated system to incubate the subsequent solution at a temperature of 80 °C to 120 °C for an effective amount of time to precipitate the CBP and the CBP variant; and using the automated system to filter the subsequent solution to remove the precipitated CBP and CBP variant from the subsequent solution to provide a deoxy-[18F]fluorocellotriose solution.

21. The method of any one of claims 1-13, further comprising: combining the deoxy-[18F]fluorocellobiose with Glc-1P and a CBP variant to provide a third solution having at least a 10-fold molar excess of the Glc-1P relative to the deoxy- [18F]fluorocellobiose; and incubating the third solution at a temperature of from 25 °C to 45 °C for a time of from 1 hour to 2 hours to provide a subsequent solution comprising deoxy-[18F]fluorocellotriose.

22. The method of claim 21, wherein the method is an automated method further comprising: using an automated system to combine the deoxy-[18F]fluorocellobiose with the Glc-1P and the CBP variant in a reactor; and using the automated system to incubate the third solution at the temperature of from 25 °C to 45 °C for the time of from 1 hour to 2 hours to provide the subsequent solution comprising deoxy-[18F]fluorocellotriose.

23. The method of claim 21 or claim 22, wherein the subsequent solution further comprises unreacted Glc-1P and the CBP variant, the method further comprising separating the CBP variant from the subsequent solution to provide a deoxy-[18F]fluorocellotriose solution.

24. The method of claim 23, wherein separating the CBP variant from the subsequent solution comprises: adding a C1-C3 alkanol to the subsequent solution to precipitate the CBP variant and unreacted Glc-1P; and removing the precipitated CBP and the precipitated unreacted Glc-1P to provide the deoxy- [18F]fluorocellotriose solution.4239-109758-02 E-080-2023-0-PCT-0225. The method of claim 23, wherein separating the CBP variant from the subsequent solution comprises: heating the subsequent solution at a temperature of from 80 °C to 120 °C for 5 minutes to 15 minutes to precipitate the CBP variant; and removing the CBP variant to provide the deoxy-[18F]fluorocellotriose solution.

26. The method of claim 23, wherein the method is an automated method and separating the CBP variant from the subsequent solution comprises: using the automated system to incubate the subsequent solution at a temperature of 80 °C to 120 °C for an effective amount of time to precipitate the CBP variant; and using the automated system to filter the subsequent solution to remove the precipitated CBP variant from the subsequent solution to provide a deoxy-[18F]fluorocellotriose solution.

27. The method of any one of claims 21-26, wherein: the deoxy-[18F]fluorocellobiose has a structure according to Formula II , wherein one or more of R1, R2, and R3is18F and the others of[18F]fluorocellotriose has a structure according to Formula IV or the deoxy-III , wherein R3is -OH, one or more of R1, R2, and R4is18F and theand the deoxy-[18F]fluorocellotriose has a structure according to Formula .4239-109758-02 E-080-2023-0-PCT-0228. The method of claim 27, wherein: (a) the deoxy-[18F]fluorocellotriose has a structure according to Formula IV and the deoxy- [18F]fluorocellotriose is: ,any combination thereof; or (b) to Formula V and the deoxy- 18[ F] ,or any combination thereof.

29. The method of claim 28, wherein the deoxy-[18F]fluorocellotriose is:

30. The method of any one of claims 17-20 or 23-29, further comprising purifying the deoxy-[18F]fluorocellotriose by: (i) flowing the deoxy-[18F]fluorocellotriose solution through a solid-phase extraction (SPE) cartridge, whereby the deoxy-[18F]fluorocellotriose solution is retained in the SPE cartridge, and eluting the deoxy-[18F]fluorocellotriose from the SPE cartridge by flowing an eluent through the SPE cartridge; or4239-109758-02 E-080-2023-0-PCT-02(ii) using the automated system to flow the deoxy-[18F]fluorocellotriose solution through a solid-phase extraction (SPE) cartridge, whereby the deoxy- [18F]fluorocellotriose solution is retained in the SPE cartridge, and using the automated system to elute the deoxy-[18F]fluorocellotriose from the SPE cartridge by flowing an eluent through the SPE cartridge.

31. The method of any one of claims 14-30, wherein an amount of the CBP variant is from 0.5 mg to 2 mg.

32. A method for enzymatic radiosynthesis of deoxy-[18F]fluorocellotriose, comprising: phosphorylating [18F]FDG to form [18F]FGlc-1P; combining the [18F]FGlc-1P with cellobiose and a CBP variant to provide a first solution having at least a 10-fold molar excess of the cellobiose relative to the [18F]FGlc-1P; and incubating the first solution at a temperature of from 25 °C to 45 °C for a time of from 1 hour to 2 hours to provide a subsequent solution comprising deoxy-[18F]fluorocellotriose, wherein the [18F]FDG has a structure according to (I), where one or more of R1, R2, R3, and R4is18F and the others of R1, R2,and wherein the deoxy-[18F]fluorocellotriose has a structure according to Formula VI, .

33. The method of claim 32, wherein an initial concentration of the cellobiose is 50 mM to 200 mM.

34. The method of claim 32 or claim 33, wherein the subsequent solution further comprises unreacted cellobiose and the CBP variant, the method further comprising separating the unreacted cellobiose and the CBP variant from the deoxy-[18F]fluorocellotriose to provide a deoxy- [18F]fluorocellotriose solution.4239-109758-02 E-080-2023-0-PCT-0235. The method of any one of claims 32-34, wherein the deoxy-[18F]fluorocellotriose is: or36. The method of claim 35, wherein the deoxy-[18F]fluorocellotriose is: .

37. The method of any one of claims 32-36, wherein: (i) an initial amount of the [18F]FDG is from 1 mCi to 200 mCi; or (ii) an amount of the CBP variant is from 0.5 mg to 2 mg; or (iii) both (i) and (ii).

38. The method of any one of claims 14-37, wherein the CBP variant is a Cellulomonas uda OCP2_M52R variant or a Cellulomonas uda His_OCP2-52R variant.